Payment overview · 2025
General Payments
$297.29
11 reported records · 8 companies
Healthcare provider profile · identity verified
Barbara Ann Williams, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LOUISVILLE, KY · NPI 1316351208
Verified facts
What the public records show
CMS Open Payments records show Barbara Ann Williams, APRN received $297.29 in general payments during 2025 across 11 reported records.
Axsome Therapeutics, Inc. accounted for 38.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Kerendia by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $113.01 | 38.0% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $47.21 | 15.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $30.41 | 10.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.29 | 9.8% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $22.56 | 7.6% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $22.27 | 7.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.37 | 5.5% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $16.17 | 5.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $297.29 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $113.01 | 2 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $47.21 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $30.41 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.29 | 2 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $16.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 298 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 251 | 89 |
| Prednisone | Prednisone | 115 | 91 |
| Losartan Potassium | Losartan Potassium | 114 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 114 | 41 |
| Ventolin Hfa | Albuterol Sulfate | 107 | 41 |
| Lisinopril | Lisinopril | 106 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 98 | 39 |
| Omeprazole | Omeprazole | 97 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 95 | 33 |
| Metformin Hcl | Metformin Hcl | 92 | 29 |
| Meloxicam | Meloxicam | 89 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 33 |
| Amitriptyline Hcl | Amitriptyline Hcl | 79 | 31 |
| Gabapentin | Gabapentin | 78 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 76 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 38 |
| Ezetimibe | Ezetimibe | 65 | 19 |
| Potassium Chloride | Potassium Chloride | 57 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 30 |
| Trazodone Hcl | Trazodone Hcl | 54 | 15 |
| Furosemide | Furosemide | 53 | 21 |
| Jardiance | Empagliflozin | 53 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 19 |
| Allopurinol | Allopurinol | 51 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 15 |
| Azithromycin | Azithromycin | 40 | 36 |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | 17 |
| Eliquis | Apixaban | 37 | 16 |
| Famotidine | Famotidine | 37 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Carvedilol | Carvedilol | 35 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 18 |
| Kerendia | Finerenone | 35 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | 11 |
| Fluconazole | Fluconazole | 32 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 30 | 12 |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Ozempic | Semaglutide | 30 | 11 |
| Linzess | Linaclotide | 29 | 11 |
| Naproxen | Naproxen | 28 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 28 | 14 |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 24 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | 11 |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | 13 |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Simvastatin | Simvastatin | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 16 |
| Ondansetron Odt | Ondansetron | 19 | 14 |
| Sertraline Hcl | Sertraline Hcl | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 15 |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 13 |
| Sucralfate | Sucralfate | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Baclofen | Baclofen | 13 | 11 |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $297.29 · 11 records | Axsome Therapeutics, Inc. | ABILIFY MAINTENA, ARISTADA, Auvelity, CAPLYTA, INVEGA SUSTENNA, Kerendia, LYBALVI, Omnipod, TZIELD | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error